Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

Variations in tuberculosis prevalence, Russian Federation: a multivariate approach.

Meshkov I, Petrenko T, Keiser O, Estill J, Revyakina O, Felker I, Raviglione MC, Krasnov V, Schwartz Y.

Bull World Health Organ. 2019 Nov 1;97(11):737-745A. doi: 10.2471/BLT.19.229997. Epub 2019 Sep 3.

2.

Where is the 'global' in the European Union's Health Research and Innovation Agenda?

Berner-Rodoreda A, Rehfuess EA, Klipstein-Grobusch K, Cobelens F, Raviglione M, Flahaut A, Casamitjana N, Fröschl G, Skordis-Worral J, Abubakar I, Ashrafian H, Agardh A, Visser L, Schultsz C, Plasència A, Jahn A, Norton R, van Leeuwen R, Hagander L, Bärnighausen T.

BMJ Glob Health. 2019 Oct 3;4(5):e001559. doi: 10.1136/bmjgh-2019-001559. eCollection 2019. Review.

3.

Tuberculosis screening in outpatient healthcare workers: lessons from a high-income, low TB burden country.

Di Bella S, Siroka A, Antonello RM, Zignol M, Maschio M, Tominz R, Cirillo D, Migliori GB, Confalonieri M, Raviglione M, Luzzati R.

Int J Tuberc Lung Dis. 2019 Sep 1;23(9):1024-1028. doi: 10.5588/ijtld.19.0060.

PMID:
31615611
4.

Tuberculosis among asylum seekers in Milan, Italy: epidemiological analysis and evaluation of interventions.

Villa S, Codecasa LR, Faccini M, Pontello MM, Ferrarese M, Castellotti PF, Senatore S, Lamberti A, Mazzola E, Perno CF, Campisi D, Saporiti M, Raviglione MC.

Eur Respir J. 2019 Oct 31;54(4). pii: 1900896. doi: 10.1183/13993003.00896-2019. Print 2019 Oct.

PMID:
31413161
5.

Precision medicine and public health interventions: tuberculosis as a model?

Temesgen Z, Cirillo DM, Raviglione MC.

Lancet Public Health. 2019 Aug;4(8):e374. doi: 10.1016/S2468-2667(19)30130-6. No abstract available.

6.

Migrants' health: Building migrant-sensitive health systems.

Villa S, Raviglione MC.

J Public Health Res. 2019 May 3;8(1):1592. doi: 10.4081/jphr.2019.1592. eCollection 2019 Mar 11. No abstract available.

7.

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives.

Pontali E, Raviglione MC, Migliori GB; and the writing group members of the Global TB Network Clinical Trials Committee.

Eur Respir Rev. 2019 May 29;28(152). pii: 190035. doi: 10.1183/16000617.0035-2019. Print 2019 Jun 30.

8.

No accountability, no results-the difficult task of advocating for tuberculosis solutions.

Raviglione M.

Lancet Infect Dis. 2019 Apr;19(4):353-354. doi: 10.1016/S1473-3099(19)30105-7. Epub 2019 Mar 22. No abstract available.

PMID:
30910429
9.

Building a tuberculosis-free world: The Lancet Commission on tuberculosis.

Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, Chin DP, Churchyard G, Cox H, Ditiu L, Dybul M, Farrar J, Fauci AS, Fekadu E, Fujiwara PI, Hallett TB, Hanson CL, Harrington M, Herbert N, Hopewell PC, Ikeda C, Jamison DT, Khan AJ, Koek I, Krishnan N, Motsoaledi A, Pai M, Raviglione MC, Sharman A, Small PM, Swaminathan S, Temesgen Z, Vassall A, Venkatesan N, van Weezenbeek K, Yamey G, Agins BD, Alexandru S, Andrews JR, Beyeler N, Bivol S, Brigden G, Cattamanchi A, Cazabon D, Crudu V, Daftary A, Dewan P, Doepel LK, Eisinger RW, Fan V, Fewer S, Furin J, Goldhaber-Fiebert JD, Gomez GB, Graham SM, Gupta D, Kamene M, Khaparde S, Mailu EW, Masini EO, McHugh L, Mitchell E, Moon S, Osberg M, Pande T, Prince L, Rade K, Rao R, Remme M, Seddon JA, Selwyn C, Shete P, Sachdeva KS, Stallworthy G, Vesga JF, Vilc V, Goosby EP.

Lancet. 2019 Mar 30;393(10178):1331-1384. doi: 10.1016/S0140-6736(19)30024-8. Epub 2019 Mar 20. Review. No abstract available.

PMID:
30904263
10.

Global Epidemiology of Tuberculosis.

Glaziou P, Floyd K, Raviglione MC.

Semin Respir Crit Care Med. 2018 Jun;39(3):271-285. doi: 10.1055/s-0038-1651492. Epub 2018 Aug 2. Review.

PMID:
30071543
11.

Ending tuberculosis in India: A political challenge & an opportunity.

Dias HMY, Pai M, Raviglione MC.

Indian J Med Res. 2018 Mar;147(3):217-220. doi: 10.4103/ijmr.IJMR_660_18. No abstract available.

12.

Global tuberculosis targets and milestones set for 2016-2035: definition and rationale.

Floyd K, Glaziou P, Houben RMGJ, Sumner T, White RG, Raviglione M.

Int J Tuberc Lung Dis. 2018 Jul 1;22(7):723-730. doi: 10.5588/ijtld.17.0835.

13.

Trends in tuberculosis in the UK.

Glaziou P, Floyd K, Raviglione M.

Thorax. 2018 Aug;73(8):702-703. doi: 10.1136/thoraxjnl-2018-211537. Epub 2018 Apr 19. No abstract available.

14.

The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era.

Floyd K, Glaziou P, Zumla A, Raviglione M.

Lancet Respir Med. 2018 Apr;6(4):299-314. doi: 10.1016/S2213-2600(18)30057-2. Review.

PMID:
29595511
15.

Tuberculosis research and development: seeding the future.

Lienhardt C, Zumla A, Gebreselassie N, Frick M, Gray G, Kasaeva T, Raviglione M.

Lancet Respir Med. 2018 Apr;6(4):242-244. doi: 10.1016/S2213-2600(18)30050-X. No abstract available.

PMID:
29595503
16.

The impact of social protection and poverty elimination on global tuberculosis incidence: a statistical modelling analysis of Sustainable Development Goal 1.

Carter DJ, Glaziou P, Lönnroth K, Siroka A, Floyd K, Weil D, Raviglione M, Houben RMGJ, Boccia D.

Lancet Glob Health. 2018 May;6(5):e514-e522. doi: 10.1016/S2214-109X(18)30195-5. Epub 2018 Mar 23.

17.

Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.

Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, Andres S, Barbova A, Borbe-Reyes A, Chin DP, Cirillo DM, Colvin C, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Hussain A, Ismail N, Kamal SMM, Khanzada FM, Kimerling M, Kohl TA, Mansjö M, Miotto P, Mukadi YD, Mvusi L, Niemann S, Omar SV, Rigouts L, Schito M, Sela I, Seyfaddinova M, Skenders G, Skrahina A, Tahseen S, Wells WA, Zhurilo A, Weyer K, Floyd K, Raviglione MC.

Lancet Infect Dis. 2018 Jun;18(6):675-683. doi: 10.1016/S1473-3099(18)30073-2. Epub 2018 Mar 21. Erratum in: Lancet Infect Dis. 2018 Mar 27;:.

18.

The World Health Organization standards for tuberculosis care and management.

Gilpin C, Korobitsyn A, Migliori GB, Raviglione MC, Weyer K.

Eur Respir J. 2018 Mar 22;51(3). pii: 1800098. doi: 10.1183/13993003.00098-2018. Print 2018 Mar. No abstract available.

19.

A New World Health Era.

Pablos-Méndez A, Raviglione MC.

Glob Health Sci Pract. 2018 Mar 30;6(1):8-16. doi: 10.9745/GHSP-D-17-00297. Print 2018 Mar 21. No abstract available.

20.

A roadmap for zoonotic tuberculosis: a One Health approach to ending tuberculosis.

Dean AS, Forcella S, Olea-Popelka F, Idrissi AE, Glaziou P, Benyahia A, Mumford E, Erlacher-Vindel E, Gifford G, Lubroth J, Raviglione M, Fujiwara P.

Lancet Infect Dis. 2018 Feb;18(2):137-138. doi: 10.1016/S1473-3099(18)30013-6. No abstract available.

PMID:
29412954
21.

Tuberculosis makes it onto the international political agenda for health…finally.

Raviglione M, Uplekar M, Weil D, Kasaeva T.

Lancet Glob Health. 2018 Jan;6(1):e20-e21. doi: 10.1016/S2214-109X(17)30449-7. Epub 2017 Nov 15. No abstract available.

22.

Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives.

Falzon D, Migliori GB, Jaramillo E, Weyer K, Joos G, Raviglione M; Global Task Force on digital health for TB.

Eur Respir J. 2017 Nov 9;50(5). pii: 1701632. doi: 10.1183/13993003.01632-2017. Print 2017 Nov. No abstract available.

23.

Harnessing the Power of Data to Guide Local Action and End Tuberculosis.

Sismanidis C, Shete PB, Lienhardt C, Floyd K, Raviglione M.

J Infect Dis. 2017 Nov 6;216(suppl_7):S669-S672. doi: 10.1093/infdis/jix374. No abstract available.

24.

Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker.

Luzzati R, Migliori GB, Zignol M, Cirillo DM, Maschio M, Tominz R, Ventura G, Patussi V, D'Ambrosio L, Centis R, Michieletto F, Trovato A, Salton F, Busetti M, Di Santolo M, Raviglione M, Confalonieri M.

Eur Respir J. 2017 Nov 2;50(5). pii: 1701414. doi: 10.1183/13993003.01414-2017. Print 2017 Nov. No abstract available.

25.

Aiming for zero tuberculosis transmission in low-burden countries.

Marais BJ, Walker TM, Cirillo DM, Raviglione M, Abubakar I, van der Werf MJ, Boehme C, Niemann S, Castro KG, Zumla A, Sintchenko V, Crook DW.

Lancet Respir Med. 2017 Nov;5(11):846-848. doi: 10.1016/S2213-2600(17)30382-X. Epub 2017 Oct 13. No abstract available.

PMID:
29033268
26.

Targeting harmful use of alcohol for prevention and treatment of tuberculosis: a call for action.

Raviglione M, Poznyak V.

Eur Respir J. 2017 Jul 13;50(1). pii: 1700946. doi: 10.1183/13993003.00946-2017. Print 2017 Jul. No abstract available.

27.

Tuberculosis control, and the where and why of artificial intelligence.

Doshi R, Falzon D, Thomas BV, Temesgen Z, Sadasivan L, Migliori GB, Raviglione M.

ERJ Open Res. 2017 Jun 21;3(2). pii: 00056-2017. doi: 10.1183/23120541.00056-2017. eCollection 2017 Apr. Review.

28.

The Internet of Things to come: digital technologies and the End TB Strategy.

Falzon D, Raviglione M.

BMJ Glob Health. 2016 Aug 12;1(2):e000038. doi: 10.1136/bmjgh-2016-000038. eCollection 2016. No abstract available.

29.

Migrant health and tuberculosis.

Raviglione MC, Mosca D.

Int J Tuberc Lung Dis. 2017 Jun 1;21(6):599-600. doi: 10.5588/ijtld.17.0209. No abstract available.

PMID:
28482951
30.

Target regimen profiles for treatment of tuberculosis: a WHO document.

Lienhardt C, Nahid P, Rich ML, Bansbach C, Kendall EA, Churchyard G, González-Angulo L, D'Ambrosio L, Migliori GB, Raviglione M.

Eur Respir J. 2017 Jan 25;49(1). pii: 1602352. doi: 10.1183/13993003.02352-2016. Print 2017 Jan. No abstract available.

31.

Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice.

Uplekar M, Atre S, Wells WA, Weil D, Lopez R, Migliori GB, Raviglione M.

Eur Respir J. 2016 Dec;48(6):1571-1581. doi: 10.1183/13993003.00956-2016. Epub 2016 Oct 20. Review.

32.

Tuberculosis.

Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, Ginsberg A, Swaminathan S, Spigelman M, Getahun H, Menzies D, Raviglione M.

Nat Rev Dis Primers. 2016 Oct 27;2:16076. doi: 10.1038/nrdp.2016.76. Review.

PMID:
27784885
33.

Zoonotic tuberculosis in human beings caused by Mycobacterium bovis-a call for action.

Olea-Popelka F, Muwonge A, Perera A, Dean AS, Mumford E, Erlacher-Vindel E, Forcella S, Silk BJ, Ditiu L, El Idrissi A, Raviglione M, Cosivi O, LoBue P, Fujiwara PI.

Lancet Infect Dis. 2017 Jan;17(1):e21-e25. doi: 10.1016/S1473-3099(16)30139-6. Epub 2016 Sep 30. Review.

PMID:
27697390
34.

Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance.

Zignol M, Dean AS, Falzon D, van Gemert W, Wright A, van Deun A, Portaels F, Laszlo A, Espinal MA, Pablos-Méndez A, Bloom A, Aziz MA, Weyer K, Jaramillo E, Nunn P, Floyd K, Raviglione MC.

N Engl J Med. 2016 Sep 15;375(11):1081-9. doi: 10.1056/NEJMsr1512438. No abstract available.

35.

Engaging health-care workers to reduce tuberculosis transmission.

Nathavitharana RR, Peters J, Lederer P, von Delft A, Farley JE, Pai M, Jaramillo E, Raviglione M, Nardell E.

Lancet Infect Dis. 2016 Aug;16(8):883-5. doi: 10.1016/S1473-3099(16)30199-2. No abstract available.

PMID:
27477968
36.

Tuberculosis 2015: Burden, Challenges and Strategy for Control and Elimination.

Raviglione M, Sulis G.

Infect Dis Rep. 2016 Jun 24;8(2):6570. doi: 10.4081/idr.2016.6570. eCollection 2016 Jun 24. Review.

37.

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.

Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjö M, Mvusi L, Niemann S, Omar SV, Qadeer E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, Wells WA, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC.

Lancet Infect Dis. 2016 Oct;16(10):1185-1192. doi: 10.1016/S1473-3099(16)30190-6. Epub 2016 Jul 7.

38.

Digital health for the End TB Strategy: developing priority products and making them work.

Falzon D, Timimi H, Kurosinski P, Migliori GB, Van Gemert W, Denkinger C, Isaacs C, Story A, Garfein RS, do Valle Bastos LG, Yassin MA, Rusovich V, Skrahina A, Van Hoi L, Broger T, Abubakar I, Hayward A, Thomas BV, Temesgen Z, Quraishi S, von Delft D, Jaramillo E, Weyer K, Raviglione MC.

Eur Respir J. 2016 Jul;48(1):29-45. doi: 10.1183/13993003.00424-2016. Epub 2016 May 26.

39.

WHO's End TB Strategy: From stopping to ending the global TB epidemic.

Uplekar M, Raviglione M.

Indian J Tuberc. 2015 Oct;62(4):196-9. doi: 10.1016/j.ijtb.2015.11.001. Epub 2016 Jan 23.

PMID:
26970458
40.

Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions.

Lienhardt C, Lönnroth K, Menzies D, Balasegaram M, Chakaya J, Cobelens F, Cohn J, Denkinger CM, Evans TG, Källenius G, Kaplan G, Kumar AM, Matthiessen L, Mgone CS, Mizrahi V, Mukadi YD, Nguyen VN, Nordström A, Sizemore CF, Spigelman M, Squire SB, Swaminathan S, Van Helden PD, Zumla A, Weyer K, Weil D, Raviglione M.

PLoS Med. 2016 Mar 2;13(3):e1001965. doi: 10.1371/journal.pmed.1001965. eCollection 2016 Mar. Review. No abstract available.

41.

The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals.

Lönnroth K, Raviglione M.

Trans R Soc Trop Med Hyg. 2016 Mar;110(3):148-50. doi: 10.1093/trstmh/trv108. Review.

42.

Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration.

Matteelli A, Lönnroth K, Mosca D, Getahun H, Centis R, D'Ambrosio L, Jaramillo E, Migliori GB, Raviglione MC.

Eur Respir J. 2016 Feb;47(2):686-8. doi: 10.1183/13993003.01597-2015. No abstract available.

43.

TB deaths rank alongside HIV deaths as top infectious killer.

Glaziou P, Floyd K, Weil D, Raviglione M.

Int J Tuberc Lung Dis. 2016 Feb;20(2):143-4. doi: 10.5588/ijtld.15.0985. No abstract available.

PMID:
26792460
44.

Numbers needed to treat to prevent tuberculosis.

Matteelli A, Lönnroth K, Getahun H, Falzon D, Migliori GB, Raviglione M.

Eur Respir J. 2015 Dec;46(6):1838-9. doi: 10.1183/13993003.01179-2015. No abstract available.

45.

Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.

Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M.

Eur Respir J. 2015 Dec;46(6):1563-76. doi: 10.1183/13993003.01245-2015. Epub 2015 Sep 24. Review.

46.

Latent Mycobacterium tuberculosis Infection.

Getahun H, Chaisson RE, Raviglione M.

N Engl J Med. 2015 Sep 17;373(12):1179-80. doi: 10.1056/NEJMc1508223. No abstract available.

PMID:
26376149
47.

Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs.

Barrera L, Cooreman E, de Dieu Iragena J, Drobniewski F, Duda P, Havelkova M, Hoffner S, Kam KM, Kim SJ, Labelle S, Lambregts K, Leimane V, Nunn P, Ramsay A, Raviglione M, Rich M, Ridderhof J, Rodrigues F, Rüsch-Gerdes S, Salfinger M, Scholten J, Selvakumar N, Shinnick T, Shul'gina M, Šķenders G, Sloutsky A, Small P, Van Deun A, Varaine F, Yagui M, Vincent V, Weyer K, Wright A, Zignol M.

Geneva: World Health Organization; 2008.

48.

The role of eHealth and mHealth in tuberculosis and tobacco control: a WHO/ERS consultation.

Falzon D, Raviglione M, Bel EH, Gratziou C, Bettcher D, Migliori GB.

Eur Respir J. 2015 Aug;46(2):307-11. doi: 10.1183/09031936.00043315. No abstract available.

49.

Latent Mycobacterium tuberculosis infection.

Getahun H, Matteelli A, Chaisson RE, Raviglione M.

N Engl J Med. 2015 May 28;372(22):2127-35. doi: 10.1056/NEJMra1405427. Review. No abstract available.

PMID:
26017823
50.

Global Tuberculosis Control: Toward the 2015 Targets and Beyond.

Dirlikov E, Raviglione M, Scano F.

Ann Intern Med. 2015 Jul 7;163(1):52-8. doi: 10.7326/M14-2210.

PMID:
25915859

Supplemental Content

Loading ...
Support Center